Pharmacotherapy of multiple sclerosis: the PROOF trial

Background: Currently approved disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) include two different interferon beta-1a (IFNB-1a) preparations: subcutaneous IFNB-1a (Rebif©) 44 μg three times weekly and intramuscular IFNB-1a (Avonex©) 30 μg once weekly. Objective: This evaluation is of the Prospective and Retrospective Long-Term Observational Study of Avonex and Rebif (PROOF), which intended to compare relative efficacy and tolerability of the two INFB-1a products. Methods: PROOF was analyzed in light of previous head-to-head studies comparing high- and low-frequency IFNB therapies. Results/conclusions: Several limitations, including a retrospective-prospective design, retrospective assessment of variables without predefined criteria, limited prospective evaluation, and inadequate sample size, necessitate careful interpretation of their Results. Ultimately, the question of long-term efficacy of high- versus low-frequency INFB therapies remains unanswered.

[1]  A. Minagar,et al.  Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF , 2008 .

[2]  D. Goodin.  A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis , 2006, Neurology.

[3]  F. Patti,et al.  Effects of interferon beta‐1a and ‐1b over time: 6‐year results of an observational head‐to‐head study , 2006, Acta neurologica Scandinavica.

[4]  J. Haas,et al.  Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®) , 2005, European journal of neurology.

[5]  V. Martinelli,et al.  A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients , 2003, Journal of neurology, neurosurgery, and psychiatry.

[6]  M. Trojano,et al.  Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy , 2003, Multiple sclerosis.

[7]  L. Kappos,et al.  A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.

[8]  D. Goodin,et al.  Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.

[9]  A. Ghezzi,et al.  Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.

[10]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[11]  D. Li,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[12]  T. Murray,et al.  Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. , 2008, Current Medical Research and Opinion.

[13]  D. Goodin.  Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. , 2006, Journal of neurology.

[14]  J. Frederiksen,et al.  A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. , 2006, Neurology.